These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance. Sriram K; Insel PA Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398 [TBL] [Abstract][Full Text] [Related]
9. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Colarusso C; Terlizzi M; Pinto A; Sorrentino R Br J Pharmacol; 2020 Nov; 177(21):4866-4872. PubMed ID: 32497257 [TBL] [Abstract][Full Text] [Related]
10. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Alexander SPH; Armstrong JF; Davenport AP; Davies JA; Faccenda E; Harding SD; Levi-Schaffer F; Maguire JJ; Pawson AJ; Southan C; Spedding M Br J Pharmacol; 2020 Nov; 177(21):4942-4966. PubMed ID: 32358833 [TBL] [Abstract][Full Text] [Related]
11. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? Sriram K; Insel PA Br J Pharmacol; 2020 Nov; 177(21):4971-4974. PubMed ID: 32639031 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H Citi V; Martelli A; Brancaleone V; Brogi S; Gojon G; Montanaro R; Morales G; Testai L; Calderone V Br J Pharmacol; 2020 Nov; 177(21):4931-4941. PubMed ID: 32783196 [TBL] [Abstract][Full Text] [Related]
13. The potential of cannabidiol in the COVID-19 pandemic. Esposito G; Pesce M; Seguella L; Sanseverino W; Lu J; Corpetti C; Sarnelli G Br J Pharmacol; 2020 Nov; 177(21):4967-4970. PubMed ID: 32519753 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 treatment by repurposing drugs until the vaccine is in sight. Phadke M; Saunik S Drug Dev Res; 2020 Aug; 81(5):541-543. PubMed ID: 32227357 [TBL] [Abstract][Full Text] [Related]
16. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014 [TBL] [Abstract][Full Text] [Related]
17. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
18. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632 [TBL] [Abstract][Full Text] [Related]
19. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Subir R; Jagat J M; Kalyan K G Diabetes Metab Syndr; 2020; 14(5):1225-1229. PubMed ID: 32683320 [TBL] [Abstract][Full Text] [Related]
20. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Choudhary S; Malik YS; Tomar S Front Immunol; 2020; 11():1664. PubMed ID: 32754161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]